Jasper Therapeutics

Jasper Therapeutics

  • Founded: 2018
  • Location: Redwood City, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Severe combined immunodeficiency
  • Drug types: IMM, ONC, HEM, GEN
  • Lead product: Briquilimab
  • Product link: https://www.jaspertherapeutics.com/pipeline/
  • Funding: $90M stock Jan 2023; $14.1M A Jan 2020; $35M A Dec 2019



job board

Short description:

Humanized Monoclonal Antibody

Drug notes:

Also Clin1/Clin2 AML/MDS, Clin1/Clin2 Fanconi's anemia, Clin1/Clin2 sickle cell disease; Clin0 chronic granulomatous disease, Clin0 MDS, Clin0 Gaucher disease, RD X-SCID; undisclosed RD thalassemias, sickle cell disease, RD autoimmune diseases

Long description:

Jasper Therapeutics develops antibody therapies for stem cell transplants. The company's mission is to make safer and potentially curative therapies possible for more patients in need. Jasper Therapeutics is developing briquilimab, a unconjugated, aglycosylated, anti-c-Kit monoclonal antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, SCF. By blocking SCF from binding to c-Kit, briquilimab causes mast cells to undergo orderly cell death. Briquilimab can be used to treat chronic mast and stem cell diseases such as chronic urticaria, lower to intermediate risk myelodysplastic syndromes (MDS), and complications from stem cell transplants.


Jasper Therapeutics
Clinical Trial Manager (CTM) - CONTRACT (Hybrid in...
Redwood City, CAHybrid|16 days ago
Jasper Therapeutics
Sr Director, Enterprise Applications
Redwood City, CAOn-site|21 days ago
Jasper Therapeutics
Director FP&A
Redwood City, CAOn-site|65 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com